Mathilde Jalving

18PUBLICATIONS
86CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsHaematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Feb 27, 2026
Correction: Govaerts et al. Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study. Cancers 2025, 17, 2425.

Chris W Govaerts, Miranda C A Kramer, Ingeborg Bosma

|Sep 10, 2025
Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome.

S Hone Lopez, S Loipfinger, A Bhattacharya

|Aug 14, 2025
Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study.

Chris W Govaerts, Miranda C A Kramer, Ingeborg Bosma

|May 05, 2025
Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data.

Lieke Lanjouw, Claire J H Kramer, Arja Ter Elst

|Mar 28, 2025
Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment.

Wellington Candido, Annemarie Cecile Eggen, Mathilde Jalving

|Jan 17, 2025
Change in Metabolic Markers and the Risk of Skin Cancer: Results from the Lifelines Cohort Study in the Netherlands.

Michael Shimelash, Grigory Sidorenkov, Bert van der Vegt

Pageof 3

Frequent Collaborators

4 joint publications

Geertruida H de Bock

2 joint publications

Jing de Haan-Du

2 joint publications

Karlijn P M Suijkerbuijk

2 joint publications

Michel W J M Wouters